Impact of China's Drug Price Negotiation on Firm Innovation, 2010-2024

Panel data from Chinese A-share listed pharmaceutical companies between 2010 and 2024 analyzes the impact of China's National Drug Price Negotiation policy. The research employs a multi-period difference-in-differences model and robustness tests like PSM-DID to examine causal effects on innovation investment and patenting. The dataset, authored by Heng Xu and last updated in 2026, is shared under a CC-BY-4.0 license.

Use Cases

• Analyzing the causal effect of price negotiation access on firm innovation investment based on the described DID model.
• Investigating heterogeneity in policy impact based on firm size and market power as mentioned in the description.
• Studying the divergence between strategic (non-invention) and substantive (invention) patenting outcomes described in the results.

Strengths

• Data covers a 15-year panel from 2010 to 2024.
• Analysis employs robust empirical methods including PSM-DID and placebo tests as described.
• The dataset is openly licensed under CC-BY-4.0.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary file format is DOCX, which may require extraction of underlying data.

Provenance

Source

Heng Xu

Collection Method

Likely compiled from financial and patent databases of Chinese A-share listed pharmaceutical companies.

Time Range

2010 to 2024

Freshness

Last updated 2026-05-11 05:28:44; freshness should be verified.

Geography

China